abstract |
A novel human MCP-1 mutant having increased glycosaminoglycan (GAG) binding affinity and knocked out or decreased GPCR activity relative to wild type monocyte chemotactic protein 1 (MCP-1) and Its use for the treatment of inflammatory diseases. |